Evidence map›Paper›PMID 23053743›Full record

ArticleClinical & experimental metastasis2013

Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations.

Alessandra Silvestri, Valerie Calvert, Claudio Belluco, Michael Lipsky, Ruggero De Maria, Jianghong Deng, Alfonso Colombatti, Francesco De Marchi, Donato Nitti, Enzo Mammano and 3 more

Open access · greenAbstract read
In one paragraph

Article in Clinical & experimental metastasis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Alessandra SilvestriCenter for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Blvd., Manassas, VA, 20110, USA.
Valerie Calvert
Claudio Belluco
Michael Lipsky
Ruggero De Maria
Jianghong Deng
Alfonso Colombatti
Francesco De Marchi
Donato Nitti
Enzo Mammano
Lance Liotta
Emanuel Petricoin
Mariaelena Pierobon
George Mason University · USCentro di Riferimento Oncologico · ITUniversity of Padua · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Maryland, Baltimore · US

Funding

Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammationR01AR068436 · NIAMS · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2015 to 2017
$1.7M
Implementation of phosphoprotein preservation technology for cancer biospecimensR33CA157403 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2011 to 2013
$922k
Microparticles for Directing Immune Cell TraffickingR21AI117425 · NIAID · GEORGE MASON UNIVERSITY · PI ESPINA, VIRGINIA ANNE, LIOTTA, LANCE ALLEN · 2015 to 2016
$418k
Microparticle Capture-Based Analysis of Lymph Node ProteomeR21AI099851 · NIAID · GEORGE MASON UNIVERSITY · PI ESPINA, VIRGINIA ANNE, LIOTTA, LANCE ALLEN · 2013 to 2014
$405k
NCI NIH HHS R33 CA157403NIAID NIH HHS R21 AI099851NIAID NIH HHS R21 AI117425NIAMS NIH HHS R01 AR068436
6 · The paper itself

Abstract

The mechanism by which tissue microecology influences invasion and metastasis is largely unknown. Recent studies have indicated differences in the molecular architecture of the metastatic lesion compared to the primary tumor, however, systemic analysis of the alterations within the activated protein signaling network has not been described. Using laser capture microdissection, protein microarray technology, and a unique specimen collection of 34 matched primary colorectal cancers (CRC) and synchronous hepatic metastasis, the quantitative measurement of the total and activated/phosphorylated levels of 86 key signaling proteins was performed. Activation of the EGFR-PDGFR-cKIT network, in addition to PI3K/AKT pathway, was found uniquely activated in the hepatic metastatic lesions compared to the matched primary tumors. If validated in larger study sets, these findings may have potential clinical relevance since many of these activated signaling proteins are current targets for molecularly targeted therapeutics. Thus, these findings could lead to liver metastasis specific molecular therapies for CRC.

Indexed as

Blotting, WesternColorectal NeoplasmsDisease ProgressionFemaleHumansMaleNeoplasm MetastasisNeoplasm ProteinsPhosphorylationProtein Array AnalysisNeoplasm Proteins

Identifiers

PMID23053743
PMCPMC5564304
OpenAlexW1967908244

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.